Fundraising Fox
BioticsAI
Techstars '23Oakland, US · 11 employees on LinkedIn · 5 known investors
Find your way into BioticsAI
Each arrow is one introduction. Sign up to fill in the first one.
Ask Fabian Lange to introduce you to Chaskin Saroff
You →Fabian · together at IBM Instana →Chaskin
Sign up to find every way you can get introduced to BioticsAI
- Your email: who you already know at BioticsAI, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the BioticsAI team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
BioticsAI develops AI-powered computer vision solutions for fetal anatomy screening and maternal ultrasound diagnostics. The company serves healthcare providers and maternal-fetal medicine specialists seeking to standardize and improve the accuracy of prenatal ultrasound assessments.
Also known as Biotics AI · BioticsAI Inc.
Founders & leadership
Investors · 5
How we know: Gurtin Ventures's portfolio page · research · caplight.com · Not right? Tell us
How we know: Startmate Launch Club's portfolio page · Not right? Tell us
How we know: the Techstars portfolio · open dataset · Top 3000 Accelerator Startups (no YC) 2026-08 · research · caplight.com · Not right? Tell us
Company profile
researched Sep 2026BioticsAI is a healthtech company developing AI-based medical imaging software for fetal and maternal ultrasound screening. Its Clinical Intelligence Platform validates the completeness and quality of fetal anomaly screenings, localizes problematic anatomical views, identifies fetal anomalies, generates documentation and provides real-time feedback to clinicians during exams. The product covers nearly 70 anatomical regions and is positioned to support compliance with AIUM and ISUOG quality guidelines.
The software includes real-time plane capture, imaging quality assessment, anatomical structure evaluation, and automated reporting with access to historical report findings. It integrates with EHR, PACS and HIS systems with real-time data syncing, and adheres to DICOM conformance standards. In January 2026 the company announced FDA 510(k) clearance for its AI software for prenatal ultrasound quality and anatomical completeness assessment; the regulatory process took just under three years including testing and validation. The company states its security posture is HIPAA-aligned, OWASP-aligned and CIS-guideline secured, with an A+ rating from GetAstra.
Founding story
CEO and co-founder Robhy Bustami was raised in a family of obstetricians, including his mother, aunt and uncle, and spent time in hospitals traveling with his mother as she provided maternal care in the U.S. He learned to code at age nine and studied computer science at UC Irvine, later working as an AI engineer at IBM alongside future CTO Chaskin Saroff. In 2021 Bustami teamed up with Salman Khan, Chaskin Saroff and Dr. Hisham Elgammal to launch BioticsAI, combining computer vision engineering with Dr. Elgammal's decade-plus of experience implementing maternal-fetal diagnostic ultrasound practices across Europe, Africa and Asia.
Business model
B2B software sold to clinics and health systems, characterized as subscription SaaS and usage-based SaaS along with services and consulting, delivered as software as a medical device at the application layer.
Subscription and usage-based software licensing, with services and consulting components.
Traction
Won the TechCrunch Disrupt 2023 Startup Battlefield competition, obtained FDA clearance in January 2026, and states that clinics are currently using the platform. Caplight lists an employee count of 9 and total funding of $180,000.
Latest developments
In January 2026 BioticsAI announced FDA clearance for its AI fetal ultrasound software. The company said its next priorities are scaling distribution across health systems nationwide and adding features for fetal medicine and reproductive health. TechCrunch also lists the company as currently raising.
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
Positioned in medical imaging AI for obstetrics and prenatal screening; comparable companies identified by Caplight include Diagnoly, BrightHeart and DeepEcho. A Stanford Medicine maternal-fetal medicine specialist has described the product as the most comprehensive AI product available for meeting AIUM and ISUOG quality guidelines.
Coverage of nearly 70 anatomical regions, FDA 510(k) clearance for prenatal ultrasound quality and anatomical completeness assessment, integration across EHR, PACS and HIS systems, and clinical validation conducted with an advisory board of maternal-fetal medicine physicians from Stanford, UC Davis, Indiana University, Maimonides Medical Center and UCLA.
Technology
Computer vision AI models trained on a diverse set of hundreds of thousands of ultrasound images, applied to real-time plane capture, imaging quality assessment, anatomical structure evaluation, anomaly detection and automated report generation. The platform interoperates with EHR, PACS and HIS systems and follows DICOM conformance standards. The company emphasizes validating consistent model performance across patient subgroups rather than only idealized cases.
Go-to-market
Direct sales through demo requests and sales contact on the company website, targeting clinics already using the platform for prenatal care, with partnerships also solicited. Following FDA clearance, the company said its next focus is scaling distribution across health systems nationwide.
Obstetricians, sonographers, maternal-fetal medicine specialists, clinics and health systems performing prenatal ultrasound screening.
Geography
Headquartered in San Francisco, California (455 Market St, Ste 1940), with a stated focus on scaling across U.S. health systems.
History
Founded in 2021 according to TechCrunch reporting on its launch (Caplight lists a 2020 founding year and a TechCrunch company profile lists 2022). Caplight records a pre-seed round in September 2021, an accelerator round in July 2023 and a grant in September 2023. The company was selected for the 2023 Startup Battlefield Top 20 at TechCrunch Disrupt, reached the six-company finalist stage, and won the competition on September 21, 2023. In January 2026 it announced FDA clearance for its fetal ultrasound AI product.
Risks & controversies
Sources note the long and uncertain regulatory pathway, with the founder describing the difficulty of ensuring reliable real-world model performance across patient demographics at highest risk of poor outcomes, and TechCrunch publishing coverage on maintaining team morale when FDA approval is not guaranteed.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 3
launches, deals, and filingsBioticsAI announced FDA clearance for its computer vision software supporting fetal ultrasound quality assessment, anatomical completeness and automated reporting. The company said the FDA process took just under three years including testing and validation.
BioticsAI was named the winner of the Startup Battlefield competition at TechCrunch Disrupt 2023, after being selected among the Top 20 and the six finalists.
Caplight records a grant dated September 21, 2023 as BioticsAI's most recent funding event; total funding raised is listed as $180,000.
$180K source ↗
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 8
primary sources listed
- BioticsAIbiotics.ai · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does BioticsAI do?
- BioticsAI builds FDA-cleared computer vision software that assesses fetal ultrasound quality and automates prenatal screening reports.
- Who founded BioticsAI?
- BioticsAI was founded by Robhy Bustami.
- Who are BioticsAI's investors?
- BioticsAI's investors include Gurtin Ventures, Startmate Launch Club, Techstars, Startmate, StartUp Health.
- Where is BioticsAI headquartered?
- BioticsAI is headquartered in Oakland, US.